Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Sosei Group ( (JP:4565) ).
Nxera Pharma, in collaboration with Cancer Research UK, has initiated a Phase 2a clinical trial for its investigational cancer immunotherapy drug HTL0039732, following successful Phase 1 results. The trial aims to evaluate the drug’s efficacy in treating advanced solid tumors, potentially offering new hope for patients with cancers resistant to current treatments, and marks a significant step in Nxera’s efforts to develop groundbreaking therapies.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen899.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing new specialty medicines to address unmet medical needs in Japan and globally. The company operates an agile commercial business in Japan and the broader APAC region, leveraging its NxWave™ discovery platform to advance a pipeline of over 30 active programs targeting obesity, metabolic disorders, neurology, neuropsychiatry, immunology, and inflammation. Nxera employs around 400 people across key locations worldwide and is listed on the Tokyo Stock Exchange.
Average Trading Volume: 767,595
Technical Sentiment Signal: Sell
Current Market Cap: Yen89.23B
Find detailed analytics on 4565 stock on TipRanks’ Stock Analysis page.